PP3M 175 mg eq.

DRUG2 trials

Conditions

Schizophrenia

Phase 3

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

CompletedNCT01515423

Janssen Research & Development, LLCSchizophrenia

Start: 2012-05-31End: 2015-03-31Updated: 2016-05-02

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

CompletedNCT01529515

Janssen Research & Development, LLCSchizophrenia

Start: 2012-05-31End: 2014-04-30Updated: 2016-05-11

2024-01-083 citations

Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.

2021-01-063 citations

Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.

2020-07-0242 citations

<p>Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies</p>

Neuropsychiatric Disease and Treatment2020-06-0119 citations

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY

Schizophrenia Bulletin2020-04-01

<p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>

Neuropsychiatric Disease and Treatment2020-03-017 citations

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia

Early Intervention in Psychiatry2019-09-1321 citations

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Brazilian Journal of Psychiatry2019-04-177 citations

S32. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE

Schizophrenia Bulletin2019-04-01

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.

2019-03-2210 citations

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.

2018-08-018 citations

Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.

2018-08-017 citations

Does Half-Life Matter After Antipsychotic Discontinuation?

The Journal of Clinical Psychiatry2017-06-1978 citations

Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.

2017-04-0126 citations

Effect of Two Long-acting Treatments, The Paliperidone Palmitate 1-month and 3-month Formulations on Caregiver Burden in European patients with Schizophrenia

European Psychiatry2017-04-01

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

Current Medical Research and Opinion2015-10-0231 citations

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

JAMA Psychiatry2015-03-29194 citations

PP3M 175 mg eq.

Sponsors

Conditions

Phase 3

Related Papers